Skip to main content

Implantable Devices

This page provides a plain English reference for implantable devices requirements under China's NMPA regulatory framework. Full content to be completed during editorial review.

Regulatory basis​

Requirements for implantable devices are set out in:

  • MDSAR 2021 (State Council Order No. 739)
  • Relevant NMPA technical guidelines published on www.cmde.org.cn
  • Applicable YY/T and GB standards

Classification implications​

Device type significantly affects classification. Consult the National Medical Device Classification Catalogue (NMDCC) for the applicable class for your specific product.

Key obligations​

Refer to CMDE technical review guidelines specific to this device type for the latest dossier requirements.

Official Sources
Disclaimer

Content on this site is written with AI assistance and is intended as a navigation aid only. Always verify against official NMPA sources before making regulatory decisions. Not affiliated with NMPA or any Chinese Government body. Not legal or regulatory advice.

Implantable devices are typically Class III and require comprehensive biocompatibility assessment per ISO 10993 including cytotoxicity, sensitization, irritation, acute systemic toxicity, and long-term biological effects (genotoxicity, carcinogenicity, reproductive toxicity) depending on contact duration and tissue type. Retrieve biological effects testing per ISO 10993-12 is often required. Long-term in-vivo performance data, retrieval/explantation protocols, and shelf-life stability studies are mandatory. Clinical evaluation must demonstrate safety and performance over the intended dwell time. Post-market surveillance and adverse event monitoring requirements are stringent for implantable devices.